[Treatment of unresectable locally advanced pancreatic cancer with combined radiotherapy and chemotherapy]. 2008

Helle Anita Jensen, and Henning Overgaard Nielsen, and Jeanette Dupont Jensen, and Claus Wilki Fristrup, and Morten Nielsen, and Per Pfeiffer
Odense Universitetshospital, Onkologisk Afdeling R, Odense C. helle.anita.jensen@ouh.fyns-amt.dk

BACKGROUND Only 10-20% of patients with pancreatic cancer are offered operation with curative intent. If this is not possible, treatment with pre-operative radiotherapy in combination with chemotherapy offers the opportunity to reduce tumor size in patients with locally advanced disease, and possibly resection with curative intent afterwards. This treatment has been offered for the last three years at the Department of Oncology, Odense University Hospital. In the following we present our results. METHODS A total of 26 patients with locally advanced unresectable pancreatic cancer were offered a combination of radiotherapy and chemotherapy. 4-6 weeks after treatment the patients were evaluated for resection. RESULTS Of the 26 patients 24 completed planned treatment. Eight patients were subsequently assessed resectable. One patient refused surgery; the other 7 patients had a R0-resection. Median survival for the whole group is 12 months. Six of the patients who went through surgery are without signs of recurrent disease after median 16 months, one patient died with recurrent disease after 37 months. CONCLUSIONS These results are similar to results from other countries. Therefore patients with locally advanced unresectable pancreatic cancer should be offered radiotherapy in combination with chemotherapy. Evaluation for surgery should be carried out 4-6 weeks after end of treatment. This strategy offers the opportunity for R0-recection and consequently cure.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011300 Preoperative Care Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed) Care, Preoperative,Preoperative Procedure,Preoperative Procedures,Procedure, Preoperative,Procedures, Preoperative
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Helle Anita Jensen, and Henning Overgaard Nielsen, and Jeanette Dupont Jensen, and Claus Wilki Fristrup, and Morten Nielsen, and Per Pfeiffer
November 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Helle Anita Jensen, and Henning Overgaard Nielsen, and Jeanette Dupont Jensen, and Claus Wilki Fristrup, and Morten Nielsen, and Per Pfeiffer
March 2003, International journal of radiation oncology, biology, physics,
Helle Anita Jensen, and Henning Overgaard Nielsen, and Jeanette Dupont Jensen, and Claus Wilki Fristrup, and Morten Nielsen, and Per Pfeiffer
April 2024, Asian journal of surgery,
Helle Anita Jensen, and Henning Overgaard Nielsen, and Jeanette Dupont Jensen, and Claus Wilki Fristrup, and Morten Nielsen, and Per Pfeiffer
July 2014, JOP : Journal of the pancreas,
Helle Anita Jensen, and Henning Overgaard Nielsen, and Jeanette Dupont Jensen, and Claus Wilki Fristrup, and Morten Nielsen, and Per Pfeiffer
November 1991, The British journal of surgery,
Helle Anita Jensen, and Henning Overgaard Nielsen, and Jeanette Dupont Jensen, and Claus Wilki Fristrup, and Morten Nielsen, and Per Pfeiffer
February 2007, Gastroenterologie clinique et biologique,
Helle Anita Jensen, and Henning Overgaard Nielsen, and Jeanette Dupont Jensen, and Claus Wilki Fristrup, and Morten Nielsen, and Per Pfeiffer
February 2001, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie,
Helle Anita Jensen, and Henning Overgaard Nielsen, and Jeanette Dupont Jensen, and Claus Wilki Fristrup, and Morten Nielsen, and Per Pfeiffer
March 1980, European journal of cancer,
Helle Anita Jensen, and Henning Overgaard Nielsen, and Jeanette Dupont Jensen, and Claus Wilki Fristrup, and Morten Nielsen, and Per Pfeiffer
January 2021, Diagnostic and interventional radiology (Ankara, Turkey),
Helle Anita Jensen, and Henning Overgaard Nielsen, and Jeanette Dupont Jensen, and Claus Wilki Fristrup, and Morten Nielsen, and Per Pfeiffer
July 2019, The Lancet. Oncology,
Copied contents to your clipboard!